Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Market Closed 04-10 16:00:00 EDT

4.76

-1.15

-19.46%

盘后1.75

-3.01-63.24%

19:59 EDT

High6.65	Low4.76	Vol8.21M
Open5.94	D1 Closing5.91	Amplitude31.98%
Mkt Cap393.05M	Tradable Cap237.85M	Total Shares82.57M
T/O48.44M	T/O Rate16.44%	Tradable Shares49.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":4.76,"timestamp":1775851200000,"preClose":5.91,"halted":0,"volume":8212440,"hourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":4.76,"latestTime":"19:59 EDT","volume":5308478,"amount":10909382.8651,"timestamp":1775865599655,"change":-3.01,"changeRate":-0.632353,"amplitude":0.653361},"delay":0,"changeRate":-0.19458544839255504,"floatShares":49968589,"shares":82572600,"eps":-3.435956,"marketStatus":"Market Closed","change":-1.15,"latestTime":"04-10 16:00:00 EDT","open":5.94,"high":6.65,"low":4.76,"amount":48442522.72944,"amplitude":0.319797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.435956,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":5.91,"preHourTrading":{"tag":"盘前","latestPrice":5.92,"preClose":5.91,"latestTime":"09:29 EDT","volume":64537,"amount":397863.183245,"timestamp":1775827799999,"change":0.01,"changeRate":0.001692,"amplitude":0.089679},"postHourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":4.76,"latestTime":"19:59 EDT","volume":5308478,"amount":10909382.8651,"timestamp":1775865599655,"change":-3.01,"changeRate":-0.632353,"amplitude":0.653361},"volumeRatio":1.6684669947017783,"impliedVol":1.2623,"impliedVolPercentile":0.644},"requestUrl":"/m/hq/s/REPL","defaultTab":"news","newsList":[{"id":"2626414399","title":"BRIEF-Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2626414399","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626414399?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:11","pubTimestamp":1775855484,"startTime":"0","endTime":"0","summary":"BRIEF-Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer PatientsApril 10 (Reuters) - Replimune Group Inc REPL.O:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T0T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626143425","title":"Replimune says FDA’s CRL for RP1 ‘disappointing’","url":"https://stock-news.laohu8.com/highlight/detail?id=2626143425","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626143425?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:10","pubTimestamp":1775855450,"startTime":"0","endTime":"0","summary":"Replimune (REPL) Group announced that the company received a complete response letter from the U.S. Food and Drug Administration for the Company’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-says-fdas-crl-for-rp1-disappointing-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-says-fdas-crl-for-rp1-disappointing-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0390134368.USD","IE00BFMHRM44.USD","BK4121","BK4588","LU0029874061.USD","BK4530","BK4585","LU1815336091.USD","REPL","BK4139","LABU","CRL","LU0128526141.USD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626714348","title":"Replimune says FDA ‘appears to have contradicted their positions’ in CRL","url":"https://stock-news.laohu8.com/highlight/detail?id=2626714348","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626714348?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:10","pubTimestamp":1775855415,"startTime":"0","endTime":"0","summary":"Replimune (REPL) said, “With the CRL, the company learned that a different review team was appointed for the resubmission and replaced the prior te...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-says-fda-appears-to-have-contradicted-their-positions-in-crl-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-says-fda-appears-to-have-contradicted-their-positions-in-crl-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00BFMHRM44.USD","LU1815336091.USD","BK4530","LABU","LU0029874061.USD","BK4585","BK4139","LU0390134368.USD","LU0757428866.USD","REPL","CRL","LU0128526141.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626435041","title":"Replimune Group: We Have No Choice but to Eliminate Jobs, Including Substantially Scaling Back Our U.S. Based Manufacturing Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2626435041","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626435041?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:04","pubTimestamp":1775855050,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T0T1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626143631","title":"Replimune: Based on FDA Feedback, Started Ignyte-3 to Satisfy Regulatory Requirement That Confirmatory Study Be Underway for Accelerated Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2626143631","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626143631?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:04","pubTimestamp":1775855050,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T0T1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148426","title":"Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148426?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:20","pubTimestamp":1775852457,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald downgraded Replimune (REPL) to Neutral from Overweight. Published first on TheFly – the ultimate source for real-time, market-mov...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-downgraded-to-neutral-from-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-downgraded-to-neutral-from-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110148","title":"Replimune downgraded to Neutral from Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110148?lang=en_us&edition=fundamental","pubTime":"2026-04-11 03:40","pubTimestamp":1775850018,"startTime":"0","endTime":"0","summary":"Piper Sandler downgraded Replimune (REPL) to Neutral from Overweight with a $4 price target Published first on TheFly – the ultimate source for rea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-downgraded-to-neutral-from-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-downgraded-to-neutral-from-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626112379","title":"Sector Update: Health Care Stocks Lower Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112379","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626112379?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:54","pubTimestamp":1775843654,"startTime":"0","endTime":"0","summary":"Health care stocks declined Friday afternoon, with the NYSE Health Care Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF  falling 1.2%.The iShares Biotechnology ETF  dropped 1.8%.In corporate news, Replimune  shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories  has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.9%.Organon  is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Ti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009355771.USD","OGN","LU2237957902.USD","LU2112291526.USD","BK4592","IE00B2B36J28.USD","LU0122379950.USD","BK4533","BK4585","IE00BFTCPJ56.SGD","LU1691799644.USD","LU1721429402.USD","IE00BJJMRZ35.SGD","IBB","LU1023059063.AUD","BK4566","LU1721429741.USD","LU1914381329.SGD","LU0289739699.SGD","BK4504","LU2065170008.USD","BK4559","LU0266013472.USD","LU1989763690.USD","ABT","SGXZ23171101.USD","LABU","LU1061106388.HKD","LU1989763427.SGD","IE00B4R5TH58.HKD","BK4568","LU2468319806.SGD","LU2065169927.USD","XLV","BK4007","LU0058720904.USD","LU2089984988.USD","LU2065171311.SGD","XBI","BK4588","LU0882574055.USD","SG9999002232.USD","BK4581","LU0114720955.EUR","ABT.AU","LU2237957811.SGD","LU2324357040.USD","REPL","IE00BJT1NW94.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626112997","title":"Replimune CRL positive for Iovance in near-term, says Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2626112997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626112997?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:43","pubTimestamp":1775842993,"startTime":"0","endTime":"0","summary":"Chardan analyst Geulah Livshits keeps a Buy rating on Iovance Biotherapeutics (IOVA) with a $16 price target after Replimune (REPL) received a seco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-crl-positive-for-iovance-in-near-term-says-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-crl-positive-for-iovance-in-near-term-says-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","REPL","LU0128526141.USD","LU1815336091.USD","LU0390134368.USD","BK4121","BK4585","LU0029874061.USD","LU0757428866.USD","BK4139","IE00BFMHRM44.USD","BK4530","IOVA","CRL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626114148","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2626114148","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626114148?lang=en_us&edition=fundamental","pubTime":"2026-04-11 01:08","pubTimestamp":1775840913,"startTime":"0","endTime":"0","summary":"One and One Green Technologies  said Friday it signed an agreement with two institutional investors to sell about 1.7 million units in a follow-on offering of its securities at $7.50 per unit, for expected gross proceeds of about $13 million.Shares slid 62%, with intraday trading volume at over 992,000, versus a daily average of roughly 196,000.Angel Studios  said Friday that it priced an underwritten public offering of 14.3 million shares of Class A common stock at $2.10 per share, raising $30 million in expected gross proceeds.Shares sank 26% following an increase in intraday trading volume to over 8.62 million from a daily average of about 762,000.Replimune Group's  biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.Shares slumped 19% as intraday trading volume soared to more than 2.94 million from a daily average of about 1.75 million.Price: 5.20, Change: -8.71, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL","BK4139","BK4108","YDDL","ANGX","BK4168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626745111","title":"BRIEF-FDA Says Data Insufficient To Conclude Effectiveness Of Replimune's vusolimogene oderparepvec","url":"https://stock-news.laohu8.com/highlight/detail?id=2626745111","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626745111?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:30","pubTimestamp":1775838642,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Says Data Insufficient To Conclude Effectiveness Of Replimune's vusolimogene oderparepvecApril 10 (Reuters) - FDA:FDA, IN COMPLETE RESPONSE LETTER: DATA WAS INSUFFICIENT TO CONCLUDE SUBSTANT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T0PN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626111521","title":"Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second Time -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2626111521","media":"Dow Jones","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626111521?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:17","pubTimestamp":1775837820,"startTime":"0","endTime":"0","summary":"Shares of Replimune Group sank on Friday after an application for an experimental skin cancer drug was rejected by the Food and Drug Administration for the second time.The agency declined to approve Replimune's lead investigational immunotherapy, RP1, in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma.At last check, Replimune shares were down 19% at $4.76, putting the stock on pace for its lowest close since October, according to Dow Jones Market Data. Trading paused twice due to volatility.The FDA rejected an application for the drug in July, two months after Vinay Prasad was appointed to lead the agency's Center for Biologics Evaluation and Research.Regulators said at the time that a clinical trial evaluating the efficacy of RP1 wasn't adequately controlled and failed to provide \"substantial evidence of effectiveness,\" though the FDA raised no safety concerns.Following that setback, Replimune resubmitted its Biologics License Application, which w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","LU0061475181.USD","LU1261432733.SGD","LU0868494617.USD","LU0882574055.USD","BK4139","LU0114720955.EUR","LU1670710588.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4532","LU2133065610.SGD","LU1868837300.USD","LU2242652126.USD","LU0267386448.USD","LU1032466523.USD","LU0306807586.USD","LU1291159041.SGD","BK4559","LU2242646821.SGD","LU0985481810.HKD","LU1868836591.USD","LU1868836757.USD","LU0306806265.USD","LU2360032135.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","BK4581","IE00B2B36J28.USD","LU1670710661.SGD","LU1093756325.SGD","LU1430594728.SGD","LU0225284248.USD","LU2125154935.USD","REPL","LABU","BK4534","IE0002141913.USD","IE00BJJMRZ35.SGD","BMY","IE00BFXG1179.USD","LU0096364046.USD","LU1670711123.USD","LU1074936037.SGD","LU0456855351.SGD","IE00BSNM7G36.USD","LU1718418525.SGD","LU0225771236.USD","LU1571399168.USD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118741","title":"Replimune's Biologics License Application for Advanced Cutaneous Melanoma Drug Rejected by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118741","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118741?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:00","pubTimestamp":1775836857,"startTime":"0","endTime":"0","summary":"Replimune Group's  biologics license application for vusolimogene oderparepvec was rejected by the US Food and Drug Administration, the regulator said in a complete response letter on Friday.The application was for vusolimogene oderparepvec plus nivolumab to treat adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 blocking antibody-based therapy, the letter said.The regulator and experts unanimously decided that the data presented in the application were \"insufficient\" to show that the treatment is effective for advanced melanoma, the letter added.Shares of Replimune Group were down 19.5% before being halted on Nasdaq at about 11:02 a.m. ET.Price: 4.76, Change: -1.15, Percent Change: -19.46","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AEIS","LABU","BK4139","BK4588","IE00B7SZL793.SGD","IE00B66KJ199.SGD","LU0757428866.USD","IE0031619046.USD","IE00B19Z4B17.USD","BK4157","REPL","LU1815336091.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626611927","title":"Replimune Group's Drug for Advanced Cutaneous Melanoma Rejected by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626611927","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626611927?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:43","pubTimestamp":1775835830,"startTime":"0","endTime":"0","summary":"Price: 4.76, Change: -1.15, Percent Change: -19.46","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B66KJ199.SGD","LU0757428866.USD","BK4588","BK4139","BK4157","IE00B7SZL793.SGD","REPL","AEIS","IE0031619046.USD","BK4585","LU1815336091.USD","IE00B19Z4B17.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626111871","title":"Replimune issued Complete Response Letter for RP1 for advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2626111871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626111871?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:35","pubTimestamp":1775835312,"startTime":"0","endTime":"0","summary":"In a Complete Response Letter addressed to Replimune (REPL) dated April 10 posted to the site of the FDA, the agency stated: “We have completed a c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-issued-complete-response-letter-for-rp1-for-advanced-melanoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-issued-complete-response-letter-for-rp1-for-advanced-melanoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","REPL","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626119662","title":"FDA, in Complete Response Letter: Data Was Insufficient to Conclude Substantial Evidence of Effectiveness of Replimune's Vusolimogene  Oderparepvec","url":"https://stock-news.laohu8.com/highlight/detail?id=2626119662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626119662?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:22","pubTimestamp":1775834578,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T0PN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626511998","title":"US FDA declines to approve Replimune's drug for advanced skin cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626511998","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626511998?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:22","pubTimestamp":1775834556,"startTime":"0","endTime":"0","summary":"US FDA declines to approve Replimune's drug for advanced skin cancerApril 10 (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Replimune's REPL.O drug for advanced skin c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4N40T17F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","LU1323610961.USD","LU1670710661.SGD","LU1585245621.USD","IE0009355771.USD","LU0225771236.USD","BK4007","LU0306806265.USD","LU0456855351.SGD","LU0985481810.HKD","LU1093756325.SGD","LU1670711040.USD","IE00BJT1NW94.SGD","BK4585","LU1571399168.USD","LU1868836757.USD","LU1989771016.USD","LU0868494617.USD","BMY","LU1868836591.USD","IE00BFXG1179.USD","LU1291159041.SGD","IE00BSNM7G36.USD","LU2125154935.USD","IE0002141913.USD","REPL","LU1430594728.SGD","LU0321505868.SGD","LU0306807586.USD","LU1670710588.SGD","LU0882574055.USD","BK4581","LU1670711123.USD","LU2242646821.SGD","LU0237698245.USD","LU1868837300.USD","LU1883839398.USD","LU0096364046.USD","BK4139","BK4559","LU1032466523.USD","LU0225284248.USD","LU2242652126.USD","BK4534","IE00BFTCPJ56.SGD","LU0267386448.USD","LU1718418525.SGD","BK4532","LU1868837136.USD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626111384","title":"Replimune sinks after FDA issues complete response letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2626111384","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626111384?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:20","pubTimestamp":1775834449,"startTime":"0","endTime":"0","summary":"11:18 EDT Replimune (REPL) sinks after FDA issues complete response letter Published first on TheFly – the ultimate source for real-time, market-mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-sinks-after-fda-issues-complete-response-letter-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-sinks-after-fda-issues-complete-response-letter-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","REPL","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626304111","title":"Replimune halted for news after dropping 19% to $4.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2626304111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626304111?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:20","pubTimestamp":1775834431,"startTime":"0","endTime":"0","summary":"11:19 EDT Replimune (REPL) halted for news after dropping 19% to $4.76 Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-halted-for-news-after-dropping-19-to-4-76-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-halted-for-news-after-dropping-19-to-4-76-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626160511","title":"Replimune Group trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2626160511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626160511?lang=en_us&edition=fundamental","pubTime":"2026-04-10 22:55","pubTimestamp":1775832924,"startTime":"0","endTime":"0","summary":"10:53 EDT Replimune (REPL) Group trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":-0.434},{"period":"1month","weight":-0.3975},{"period":"3month","weight":-0.4072},{"period":"6month","weight":0.0508},{"period":"1year","weight":-0.3121},{"period":"ytd","weight":-0.5103}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.056633},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.048711},{"month":6,"riseRate":0.857143,"avgChangeRate":0.223071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}